Company Profile
Materialise Stock Price, News & Analysis
- Ticker:
- MTLS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Materialise is followed within the biotech universe for its exposure to catalyst-driven execution.
Stock performance
6.51 USD (+0.31%)
Close
Last updated: June 23, 2026 at 00:00
378.03M USD
Market cap
Why the stock is moving
MTLS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Materialise is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Materialise is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Materialise follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Materialise sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Materialise houdt jaarlijkse aandeelhoudersvergadering op 16 juni 2026
Source: Materialise
- 04
Materialise to Hold Annual Shareholders’ Meeting on June 16, 2026
Source: Materialise
- 05
Materialise Reports First Quarter 2026 Results
Source: Materialise
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Materialise (MTLS)?
Materialise (MTLS) most recently closed at 6.51 USD, a +0.31% move versus the previous session.
What is the market cap of Materialise (MTLS)?
Materialise currently has a market capitalization of 378.03M USD on BioPharmSignal.
What does Materialise do?
Materialise is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is MTLS stock listed?
Materialise (MTLS) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Materialise is followed within the biotech universe for its exposure to catalyst-driven execution., Biotechnology.
What is Materialise?
Materialise is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
Which conditions is Materialise targeting with Materialise?
Materialise is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
What is Investors?
Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.